Estimated Annual Spending on Aducanumab in the US Medicare Program

Area of Science:

• Neurology
• Health Economics
• Pharmacoeconomics

Background:

• Alzheimer's disease poses a significant public health challenge.
• Aducanumab is an FDA-approved therapy for specific stages of Alzheimer's disease.
• Understanding treatment costs is crucial for healthcare system planning.

Purpose of the Study:

• To estimate the upper and lower bounds of annualized Medicare costs associated with aducanumab administration.
• To analyze the economic implications for beneficiaries with approved indications of mild cognitive impairment or mild dementia.

Main Methods:

• Cross-sectional study design.
• Analysis of Medicare cost data.
• Inclusion of beneficiaries meeting criteria for mild cognitive impairment or mild dementia.

Main Results:

• Calculated a range for annual Medicare expenditures per patient for aducanumab.
• Identified key cost drivers for aducanumab therapy within the Medicare population.

Conclusions:

• The findings offer essential data for budget impact models of aducanumab.
• Cost-effectiveness analyses are needed to further evaluate aducanumab's value proposition.